Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Commvault Systems (NASDAQ: CVLT); MongoDB (NASDAQ: MDB); New Era Energy & Digital (NASDAQ: NUAI); and Regeneron Pharmaceuticals (NASDAQ: REGN) Shareholders
-
SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ViroMissile, Inc., a cancer immunotherapy company pioneering the IDOV™ (Intravenously Deliverable Oncolytic Virus) platform, today announced the...
-
Investigational Oral Candidate JOTROL™ Addresses a Parkinson’s Disease Market with No Current Disease-modifying Therapies Available Jupiter, FL, May 27, 2026 (GLOBE NEWSWIRE) -- Jupiter...
-
Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the cccDNA reservoirData on the preclinical characteristics of the Aligos/Amoytop ASO...
-
NEOTORCH has finished its final analysis and met all the primary endpoints of EFS and MPR rate in the stage Ⅱ-Ⅲ NSCLC patients.
-
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN). Such...
-
Notice: Molina Healthcare(NYSE: MOH); MongoDB (NASDAQ: MDB); New Era Energy & Digital (NASDAQ: NUAI); and Regeneron Pharmaceuticals (NASDAQ: REGN)
-
-Topline Data Release Targeted Late Summer 2026- CARSON CITY, Nev., May 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing...
-
Artios announces first patient dosed in randomized Phase 2 POLKA study evaluating DNA Polθ inhibitor ART6043 in gBRCA-mutated HER2-negative breast cancer.
-
MDS-UPDRS scores remained stable and durable across overall study population after 150 days of treatment with GT-02287 Differential response between participants with low and high baseline GluSph...